The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa.
about
Nanomedicine approaches for corneal diseasesNanomedicine in the application of uveal melanomaChitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cellsBioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue.Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems.Mucoadhesive microdiscs engineered for ophthalmic drug delivery: effect of particle geometry and formulation on preocular residence time.Augmented cytotoxicity of hydroxycamptothecin-loaded nanoparticles in lung and colon cancer cells by chemosensitizing pharmaceutical excipients.Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug deliveryNanomedicine strategies for treatment of secondary spinal cord injury.CSM enhances the filtration bleb survival in rabbit model of experimental glaucoma surgery.Novel PLGA-based nanoparticles for the oral delivery of insulin.The potential of chitosan in ocular drug delivery.Cationic vectors in ocular drug delivery.Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion.Bioadhesive properties of pegylated nanoparticles.The potential of chitosan for the oral administration of peptides.The performance of nanocarriers for transmucosal drug delivery.Dense chitosan surgical membranes produced by a coincident compression-dehydration process.Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives.Recent perspectives in ocular drug delivery.Nanoparticles as protein and gene carriers to mucosal surfaces.Chitosan nanoparticles for drug delivery to the eye.Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.Redefining tissue engineering for nanomedicine in ophthalmology.Ocular drug delivery - a look towards nanobioadhesives.Nanoparticles in biological systems.Novel drug delivery systems for glaucoma.Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale.Nanomaterials for ocular drug delivery.Theory, fabrication and applications of microfluidic and nanofluidic biosensors.Ocular application of chitosan.Poly(ϵ-caprolactone) microcapsules and nanocapsules in drug delivery.Nanoparticles laden in situ gelling system for ocular drug targeting.Topical delivery of ocular therapeutics: carrier systems and physical methods.Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions.Advances in ophthalmic drug delivery.Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol.Mucin-mediated nanocarrier disassembly for triggered uptake of oligonucleotides as a delivery strategy for the potential treatment of mucosal tumours.Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone ButyrateNanoparticles for drug delivery to the anterior segment of the eye.
P2860
Q27022253-9E7A0E7D-CD9A-4441-A1EE-F873C7FE9098Q28079572-0C4682E0-170D-420B-9F08-2DD7D95F2176Q28475072-96AC26B5-43EB-4838-A369-EF911A4F9DCCQ33321483-56DD8710-0F4C-4D39-8800-221D75C20938Q33733579-1AE9F7AD-F1F6-47C7-AAB6-1C2D02A070B1Q34038784-7CB15BBC-B965-4339-A221-53799D70EF01Q35007929-95016DC7-2D48-4A3D-80C8-9906955290BAQ35043797-E9ABDDDF-79E6-46A9-9434-7CD11B5542B3Q35063603-614F005F-94BC-4FC9-8387-F0C57CBCFFC2Q35161197-F547B65B-DFC4-4F40-BC0B-871754DEC713Q35248662-E2CA5709-15AD-437F-B100-CB276B60D654Q35624563-C5E3BA8C-0048-43E0-9F80-84B24150A020Q35994783-5947F2D9-08C1-4C66-9AB8-78256FF40775Q36032477-DFCBC273-250E-45D8-86D1-BD8AF92CBB05Q36316693-E73C9678-D9DE-4BA6-BF5A-CD6C43E81551Q36316822-1EAF0DAD-EEA4-4242-9E33-F3C2AA63098AQ36527739-7A550B0F-039B-40CF-ADDA-6286492E5F41Q36756873-112E11B5-1785-46A4-81B2-695E319891AFQ37004099-D469C834-5BE0-4010-A870-4F32C27E1F5DQ37256549-E5836C9C-AD6C-4FDD-9936-A8CE412547B0Q37331802-D3F60A69-00A2-4E4D-8BC5-5E3933DA5C41Q37416144-01EAB705-4B61-4225-864C-F0F2D5763E0AQ37627442-63FA4F36-B60C-45B2-8B08-B152C0E8CCE3Q37782373-442F3BA4-C77C-403C-AF2A-DDD813614F29Q37822756-6F00E6B1-2B2D-4123-9E3A-10A8CE3091FEQ37835203-267071D3-3064-44A3-9971-6A01E917BAADQ37862989-94ED0785-F3A8-4F43-9491-AED2DEF946D2Q37877717-FAE6171F-750E-4AAE-8DDC-75D6393F33E9Q38003088-7DC08587-0665-4A34-9175-C3D14C2260C8Q38003136-EAF61814-7419-4AE7-A26F-93BA3F126E90Q38005199-F8242028-90CA-434D-88BC-677F9341BC4BQ38079611-C7C11775-7F9D-4F09-AE5E-9E9397632F60Q38105564-963694E3-DE5B-46B1-8D89-8D247BDFCF8DQ38196446-971CB33B-91B0-4F14-AAD3-565D550E7129Q38227621-E926FAA7-9539-4139-9201-7A0ECB4CDC40Q38297129-A20FF9AF-ED39-4AC6-959E-A7F7A7E4E55EQ38716544-350C57EE-FD04-4828-9E7D-1FFD946CC13BQ38809725-7B577BD6-023B-46DE-8CD7-0C74DEDEE968Q38862840-EC69C592-4395-4390-B937-95BCB148D90AQ39230212-B5E0E6B7-E74D-4BAE-995A-63DEC60B1D6B
P2860
The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The effect of a PEG versus a c ...... rriers with the ocular mucosa.
@ast
The effect of a PEG versus a c ...... rriers with the ocular mucosa.
@en
type
label
The effect of a PEG versus a c ...... rriers with the ocular mucosa.
@ast
The effect of a PEG versus a c ...... rriers with the ocular mucosa.
@en
prefLabel
The effect of a PEG versus a c ...... rriers with the ocular mucosa.
@ast
The effect of a PEG versus a c ...... rriers with the ocular mucosa.
@en
P2093
P1476
The effect of a PEG versus a c ...... arriers with the ocular mucosa
@en
P2093
Alejandro Sánchez
Angela M De Campos
Pilar Calvo
P356
10.1016/S0928-0987(03)00178-7
P407
P577
2003-09-01T00:00:00Z